Canaccord Genuity Starts BioNTech (BNTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $91.29 --0%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 40
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 40
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee initiates coverage on BioNTech (NASDAQ: BNTX) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.
Shares of BioNTech closed at $17.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Starts Entergy Corp (ETR) at Buy
- Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy
- Oppenheimer Starts Leonardo DRS (DRS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
